Hoe farmaseutyske bedriuwen generyske medisinen yn Jeropa fertrage
March 28, 2025 · Frisian News
European pharmaceutical giants use legal tactics and patent strategies to block cheaper generic versions of drugs from reaching patients. Health authorities struggle to enforce timely access as companies exploit loopholes in European regulations.
FryskFoarige wike blokkearren Italjaanske regelders in generyske ferzje fan in faak brûkt hertmedisyn omdat de oarspronklike patinthâlder in lêste-minút klacht yntsjinne oer de etikettering. It medisyn wurket identyk oan de merkferzje. It kostet de helte safolle. Dochs sille pasjinten yn Itaalje noch seis moannen wachtsje, en it farmaseutysk bedriuw krijt seis moannen ekstra monopolywinsten. Dizze sêne werhellet him eltse wike yn Jeropa.
Farmaseuten brûke in strategy dy't 'evergreening' neamd wurdt om generyske middels út winkels te hâlden. Se bringe lytse wizigjingen oan yn medisijnformules, tsjinje nije patinten yn, ferlingje eksklusiviteitsperioaden, of tsjinje juridyske beswieren yn tsjin generyske goedkardingen krekt foardat dizze fan krêft wurde. It Jeropeeske patintrjocht jout dizze bedriuwen meardere mooglikheden om te obstruearjen. Patintburo's yn Brussel, Amsterdam en oare stêden ferwurkje jierliks hûnderten fan dizze blokkeearaksjes. Net folle nasjonale regearingen hawwe de middels om fluch tsjin te striden.
De kosten falle op pasjinten en belestingbetelders. Generyske medisinen koste 80 oant 90 prosint minder as oarspronklike. As bedriuwen generyske middels twa of trije jier fertrage, jouwe Jeropeeske sûnensystemen miljarden út oan ûnnedige útjeften. Dútslân allinne ferliest rûchwei 2 miljard euro it jier troch fertrage generyske ynfierring. Lytsere lannen fiele noch skerper budzjetdruk. Sikehûzen rasjonearje behanneljingen, snoeie personiel yn, of stelle apparatueroankeapen út omdat generyske prizen nea sa fluch komme as se komme soene.
Jeropeeske Uny-regelders witte dat dit bart. It Jeropeesk Genêsmiddelenburo en nasjonale sûnensautoriteiten hawwe it probleem oankaart yn rapporten fan mear as tsien jier lyn. Dochs hat Brussel wegere terminen oan te skerpen of straffen foar ûnsinnige patintclaims yn te stellen. Farmaseutyske lobbys beynfloedzje belied. Dizze bedriuwen sette hûnderten advokaten yn en jouwe miljoenen út oan politike tagong. Lytse pasjintegroepen en generyske fabrikanten hawwe deselde slagkrêft net. It systeem wurket krekt sa't de sterkste partij it ûntworpen hat.
Generyske fabrikanten en sûnensfoarstanners dringe oan op flugger beoardielingsprosedures en straffen foar misbrûk. Guon lannen hawwe fersnelde goedkardingspaden mei beskieden súkses útbesocht. De echte oplossing fereasket politike wil. Regearingen moatte beslisse oft hja pasjinten of bedriuwen tsjinje. Oant hjirta bliuwt it antwurd yn Jeropa ûndúdlik.
Last week, Italian regulators blocked a generic version of a common heart drug because the original patent holder filed a last-minute complaint about labeling. The drug works identically to the brand name version. It costs half the price. Yet patients in Italy will wait another six months for access, and the pharmaceutical company gets six more months of monopoly sales. This scene repeats across Europe every week.
Pharmaceutical firms deploy a strategy called 'evergreening' to keep generics off shelves. They make small changes to drug formulations, apply new patents, extend exclusivity periods, or file legal challenges to generic approvals just before they take effect. European patent law gives these companies multiple opportunities to obstruct. Patent offices in Brussels, Amsterdam, and other capitals process hundreds of these blocking actions annually. Few national governments have the resources to fight them quickly.
The cost falls on patients and taxpayers. Generic drugs cost 80 to 90 percent less than originals. When companies delay generics by two or three years, European health systems spend billions in unnecessary expenses. Germany alone loses roughly 2 billion euros yearly to delayed generic entry. Smaller countries face even sharper budget pressures. Hospitals ration treatments, cut staff, or defer equipment purchases because generic prices never arrive as fast as they should.
European Union regulators know this happens. The European Medicines Agency and national health authorities have flagged the problem in reports dating back a decade. Yet Brussels has refused to tighten timelines or impose penalties for frivolous patent claims. Pharmaceutical lobbies influence policy. These companies employ hundreds of lawyers and spend millions on political access. Small patient groups and generic manufacturers lack the same firepower. The system works exactly as the strongest side designed it.
Generic manufacturers and health advocates push for faster review processes and penalties for abuse. Some nations have tested accelerated approval paths with modest success. The real fix requires political will: governments must decide whether they serve patients or corporations. So far, across Europe, the answer remains unclear.
Published March 28, 2025 · Frisian News · Ljouwert, Fryslân